TULSA-PRO, which received CE Mark approval in April, combines real-time magnetic resonance imaging with transurethral, robotically-driven therapeutic ultrasound and closed-loop thermal feedback control designed to provide precise ablation of the prostate while simultaneously protecting critical surrounding anatomy from potential side effects. The company announced the first European sales of TULSA-PRO systems in Spain, the United Kingdom, and Germany earlier this year.
“On behalf of everyone at the company, I would like to extend my sincere thanks to Frost & Sullivan for this award,” said Arun Menawat, Profound’s CEO. “It provides further validation that TULSA-PRO represents an attractive clinical option for patients with localized prostate cancer and comes at an opportune time as we continue to build awareness and adoption of this important new therapy in Europe.”
Frost & Sullivan recognizes companies from a range of regional and global markets for their leadership, technological innovation, customer service and strategic product development. This year, Profound’s TULSA-PRO system stood out from its competitors based on its proprietary inside-out approach to ablating prostate tissue, and by balancing patient outcomes with treatment cost. The award will be presented to Profound during a banquet held at The Westin Paris - Vendôme hotel in Paris, France, on Nov. 9.
“Profound Medical's introduction of the TULSA-PRO system to the European market can be attributed to the extensive experience of its management team in commercializing medical devices, including ablation technologies,” said Arjunvasan Ambigapathy, an industry analyst in technical insights for Frost & Sullivan. “By demonstrating industry-leading best practice initiatives, the company succeeded in exclusively differentiating its offering as a safe and effective alternative to existing expensive treatment modalities for prostate cancer. The competitive advantage built by Profound Medical has improved its brand reputation as being the only company in the world developing and commercializing a transurethral ultrasound ablation technology.”
For the millions of men currently living with prostate cancer, and the thousands more who are diagnosed with it every year, current treatment options often mean having to make difficult choices based on potential side effects that can significantly impact quality of life.
Established in 2008, Profound Medical is commercializing TULSA-PRO. The Canadian firm is sponsoring a multicenter, prospective U.S. Food and Drug Administration-registered clinical trial, TACT, which is designed to further demonstrate the safety and effectiveness of the technology.